Drug news
Early results for SM101 (Suppremol) are encouraging for ITP
Interim results from a Phase 1b/IIa study of SM 101 from Munich-based SuppreMol GmbH for the treatment of primary Immune Thrombocytopenia were encouraging. SM 101 is a recombinant, soluble, non glycosylated version of the Fc receptor IIb. The protein binds to autoantibody/autoantigen complexes and blocks the activation of Fc receptors on the surface of immune cells. As a result, the immune response is down regulated and triggering of the inflammation cascade is prevented. The drug is also in an early trial for SLE.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.